Skip to main content

Research Repository

Advanced Search

Targeting protein kinase CK2 in the treatment of cholangiocarcinoma

Jayaraman, Padma Sheela; Gaston, Kevin

Targeting protein kinase CK2 in the treatment of cholangiocarcinoma Thumbnail


Authors

SHEELA JAYARAMAN Sheela.Jayaraman@nottingham.ac.uk
Professor of Cancer Biology and Gene Regulation



Abstract

Cholangiocarcinoma (CCA) is a disease with a very poor prognosis and limited treatment options. Although targeted therapies directed towards specific mutations found in CCA are becoming available and are showing great potential, many tumors do not carry actionable mutations and, in those that do, the emergence of drug resistance is a likely consequence of treatment. Therapeutic targeting of enzymes and other proteins that show elevated activity in CCA cells but which are not altered by mutation is a potential strategy for the treatment of target negative and drug-resistant disease. Protein kinase CK2 (CK2) is a ubiquitously expressed kinase that has increased expression and increased activity in a variety of cancer types including CCA. Several potent CK2 inhibitors are in pre-clinical development or under assessment in a variety of clinical trials often in combination with drugs that induce DNA damage. This review outlines the importance of CK2 in CCA and assesses the progress that has been made in the evaluation of CK2 inhibition as a treatment strategy in this disease. Targeting CK2 based on the expression levels or activity of this protein and/or in combination with drugs that induce DNA damage or inhibit cell cycle progression, could be a viable option for tumors that lack actionable mutations, or for tumors that develop resistance to targeted treatments.

Citation

Jayaraman, P. S., & Gaston, K. (2021). Targeting protein kinase CK2 in the treatment of cholangiocarcinoma. Exploration of Targeted Anti-tumor Therapy, 2(5), 434-447. https://doi.org/10.37349/etat.2021.00055

Journal Article Type Article
Acceptance Date Aug 31, 2021
Online Publication Date Oct 9, 2021
Publication Date Oct 31, 2021
Deposit Date Nov 24, 2021
Publicly Available Date Nov 26, 2021
Journal Exploration of Targeted Anti-tumor Therapy
Print ISSN 2692-3114
Electronic ISSN 2692-3114
Publisher Open Exploration
Peer Reviewed Peer Reviewed
Volume 2
Issue 5
Pages 434-447
DOI https://doi.org/10.37349/etat.2021.00055
Public URL https://nottingham-repository.worktribe.com/output/6786586
Publisher URL https://www.explorationpub.com/Journals/etat/Article/100255

Files





You might also like



Downloadable Citations